A dual role for PGLYRP1 in host defense and immune regulation during B. pertussis infection

Reviewer #1 (Public review):

Summary:

The authors aim to demonstrate that PGLYRP1 plays a dual role in host responses to B. pertussis infection. PGLYRP1 signaling is known to activate bactericidal responses due to recognition of peptidoglycan. Through NOD1 activation and TREM-1 engagement, it appears PGLYRP1 also has immunomodulator activities. The authors present mouse knockout studies and gene expression data to illustrate the role of PGLYRP1 in relation to B. pertussis peptidoglycan. Mice lacking PGLYRP1 had slightly lower pathology scores. When TCT peptidoglycan was removed from the bacteria, surprisingly IL23A, IL6, IL1B, and other pro-inflammatory genes encoding cytokines increased. The relationship to TCT and PGLYRP1 suggests the pathogen uses this strategy to decrease immune activation. The authors went on to show the relationship between PGLRP1 and TREM-1 as mediated by PGN using various versions of peptidoglycan. The study presents multiple angles of data to back up its findings and demonstrates an interesting strategy used by B. pertussis to downregulate innate responses to its presence during infection.

Strengths:

Use of knockout mice of the key factor being considered, paired with isogenic B. pertussis strains, to reveal the mechanism of immune modulation to benefit the bacteria. The authors used in vivo gene expression paired with in vivo assays to establish each aspect of the mechanism.

Weaknesses:

The main focus was on innate responses, and some analysis of antigen-specific antibody responses could improve the impact of the findings.

Reviewer #2 (Public review):

Since its original discovery, the mechanistic basis for TCT-mediated pathogenesis of Bordetella pertussis has been a moving target and difficult to uncouple from confounding variables. The current study provides some exciting data that suggest PGLYRP-1 modulates host responses upon 'activation' by TCT. While there are some strengths associated with the unbiased approaches and collective data to support the claims associated with TCT and PGLYRP-1's function in this system, caution should be used when interpreting and extrapolating some of the information provided. For instance, the amount and purity of TCT used in the studies are unclear, and the in vitro activity of PGLYRP1 on B. pertussis is questionable. Different mouse backgrounds are used for various assays throughout, and it is known that the PRRs vary in these systems, so the confounding variables are difficult to uncouple. Additional concerns include the types of statistical tests being performed to support some of the claims and the relevance of using whole, intact PG sacculi from other species for comparative studies with a fragment of released PG (i.e., TCT).

Reviewer #3 (Public review):

Summary:

This study evaluates the contributions of the mammalian PG-binding protein PGLYRP1 to Bordetella infection. The authors find potential roles for PGLYRP1 in both bacterial killing (canonical) and regulation of inflammation (non-canonical). While these are interesting findings and the idea that PG fragment release has differential impacts on infection depending on fragment structure, the study is limited by the lack of connection between the in vivo and in vitro experiments, and determining the precise mechanism of how PGLYRP1 regulates host responses and bacterial fitness during infection requires further study.

Strengths:

(1) The combination of scRNAseq with in vitro and in vivo assays provides complementary views of PGLYRP1 function during infection.

(2) The use of TCT-deficient B. pertussis provides a useful control and perturbation in the in vitro assays.

Weaknesses:

(1) The study does not ultimately resolve the initial early versus late phenotype divergence. While the in vitro assays suggest explanations for their in vivo observations, further mechanistic links are lacking and necessary for the author's conclusions throughout. To state one example, what is the early and late infection phenotype of TCT- Bp in mice lacking PGLYRP1? RNAseq data are reported from these mice, but there are no burden or pathology studies. Furthermore, what are the neutrophil phenotypes (NOD-1/TREM-1 activation) in vivo? And are they dependent on PGLYRP1 and/or TCT?

(2) It is unclear whether or how the NOD1 and TREM-1 pathways interact.

(3) Many of the study's conclusions rely on the use of HEK293 reporter lines in the absence of bacterial infection, which may not be physiologically representative.

(4) The methods lack detail overall, and the experimental procedures should be described more concretely, especially for the scRNAseq datasets.